JP2015502387A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502387A5
JP2015502387A5 JP2014548061A JP2014548061A JP2015502387A5 JP 2015502387 A5 JP2015502387 A5 JP 2015502387A5 JP 2014548061 A JP2014548061 A JP 2014548061A JP 2014548061 A JP2014548061 A JP 2014548061A JP 2015502387 A5 JP2015502387 A5 JP 2015502387A5
Authority
JP
Japan
Prior art keywords
hal
formula
alkyl
independently
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548061A
Other languages
English (en)
Japanese (ja)
Other versions
JP6129203B2 (ja
JP2015502387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076595 external-priority patent/WO2013092979A1/en
Publication of JP2015502387A publication Critical patent/JP2015502387A/ja
Publication of JP2015502387A5 publication Critical patent/JP2015502387A5/ja
Application granted granted Critical
Publication of JP6129203B2 publication Critical patent/JP6129203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548061A 2011-12-22 2012-12-21 α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤 Expired - Fee Related JP6129203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579076P 2011-12-22 2011-12-22
EP11195107.5 2011-12-22
EP11195107 2011-12-22
US61/579,076 2011-12-22
PCT/EP2012/076595 WO2013092979A1 (en) 2011-12-22 2012-12-21 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Publications (3)

Publication Number Publication Date
JP2015502387A JP2015502387A (ja) 2015-01-22
JP2015502387A5 true JP2015502387A5 (enExample) 2016-02-18
JP6129203B2 JP6129203B2 (ja) 2017-05-17

Family

ID=48667763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548061A Expired - Fee Related JP6129203B2 (ja) 2011-12-22 2012-12-21 α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤

Country Status (15)

Country Link
US (1) US9688702B2 (enExample)
EP (1) EP2793900B1 (enExample)
JP (1) JP6129203B2 (enExample)
KR (1) KR20140114391A (enExample)
CN (1) CN104321060B (enExample)
AU (1) AU2012356890B2 (enExample)
BR (1) BR112014015363A2 (enExample)
CA (1) CA2860142C (enExample)
EA (1) EA201400735A1 (enExample)
ES (1) ES2699267T3 (enExample)
HK (1) HK1206261A1 (enExample)
IL (1) IL233200A (enExample)
MX (1) MX352652B (enExample)
SG (2) SG10201605152SA (enExample)
WO (1) WO2013092979A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014086664A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole boronic acid compounds
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6324409B2 (ja) * 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP2016509594A (ja) * 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9988421B2 (en) 2014-01-10 2018-06-05 Cornell University Dipeptides as inhibitors of human immunoproteasomes
FI3604316T3 (fi) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (ru) * 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
EP3193904B1 (en) 2014-08-18 2025-10-01 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
ES2873000T3 (es) * 2014-10-01 2021-11-03 Merck Patent Gmbh Derivados del ácido borónico.
JP6662865B2 (ja) 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
KR20170062518A (ko) 2014-10-01 2017-06-07 메르크 파텐트 게엠베하 보론산 유도체
CN107108660B (zh) * 2014-10-01 2020-09-15 默克专利股份公司 硼酸衍生物
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP3362754B1 (en) 2015-10-15 2021-12-22 Cornell University Proteasome inhibitors and uses thereof
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
IL272806B2 (en) 2017-08-24 2023-09-01 Merck Patent Gmbh The history of boronic acid, its preparation and pharmaceutical preparations containing it
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3694605A4 (en) 2017-10-11 2021-10-27 Cornell University PEPTIDOMIMETIC PROTEASOME INHIBITORS
CN107556336A (zh) * 2017-10-16 2018-01-09 康化(上海)新药研发有限公司 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法
EP3710457B1 (en) 2017-11-16 2022-08-03 Principia Biopharma Inc. Immunoproteasome inhibitors
WO2019099582A1 (en) 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
CN108130370B (zh) * 2018-01-05 2020-11-17 武汉惠康达科技有限公司 Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN112469480A (zh) 2018-07-26 2021-03-09 默克专利股份公司 硼酸衍生物
WO2020112542A1 (en) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
JP7758028B2 (ja) * 2021-03-05 2025-10-22 Agc株式会社 化合物、化合物の製造方法及び表面処理剤の製造方法
CA3227452A1 (en) 2021-07-29 2023-02-02 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
WO2023061445A1 (zh) * 2021-10-14 2023-04-20 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
TW202529745A (zh) 2023-11-21 2025-08-01 美商維納拓爾斯製藥公司 經口遞送之β-內醯胺酶抑制劑之檸檬酸鹽配位錯合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7332343B2 (en) * 2004-01-16 2008-02-19 Board Of Regents, The University Of Texas System Determining enantiomeric excess using indicator-displacement assays
NZ598172A (en) * 2004-03-30 2013-08-30 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
CA2668662A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MY161991A (en) * 2007-08-06 2017-05-31 Millennium Pharm Inc Proteasome inhibitors
JP5600595B2 (ja) * 2007-10-16 2014-10-01 ミレニアム ファーマシューティカルズ, インコーポレイテッド プロテアソーム阻害剤
TW200936143A (en) * 2007-11-13 2009-09-01 Protez Pharmaceuticals Inc Beta-lactamase inhibitors
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2011235227B2 (en) * 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2563126B1 (en) 2010-04-30 2016-05-11 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators

Similar Documents

Publication Publication Date Title
JP2015502387A5 (enExample)
JP2022541467A (ja) オーロラキナーゼ阻害剤およびその使用
AU2020262221B2 (en) 4H-pyrrolo(3,2-c)pyridin-4-one compounds
EA023826B1 (ru) Дигидропиримидинизохинолиноны и содержащие их фармацевтические композиции для лечения воспалительных нарушений
JP2016534146A5 (enExample)
JP2008503591A5 (enExample)
JP2015163632A5 (enExample)
JP2016500661A5 (enExample)
BR112015023142B1 (pt) Moduladores do p2x7, seu uso, processo de preparação e composição farmacêutica que os compreende
KR20180093925A (ko) 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법
JP2011523945A5 (enExample)
JP2013536259A5 (enExample)
JP2016530338A5 (enExample)
JP2015501327A5 (enExample)
WO2007113289A1 (en) Benzofuran compounds as ep1 receptor antagonists
JP7710215B2 (ja) ピロール化合物
JP2019501927A5 (enExample)
KR20210005668A (ko) Hpk1 억제제, 그의 제조 방법 및 응용
JP2017508733A5 (enExample)
JP2016532669A5 (enExample)
JP2015535851A5 (enExample)
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
ES2548258T3 (es) Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
JP2014505033A5 (enExample)
JP2019532092A5 (enExample)